Abbey Diaz

Has grant

Senior Research Fellow

Australian National University
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Towards optimal and equitable cardiovascular care pathways for Aboriginal and Torres Strait Islander people with cancer

Open Date: 2022-01-01

Close Date: 2024-12-01

Grant: Close

A feasibility study of an Indigenous patient navigator-led brief health behaviour intervention for Indigenous cancer survivors

Open Date: 2021-11-01

Close Date: 2023-05-01

Grant: Close

UQ Faculty of Medicine 5-year Research Fellowship

Open Date: 2021-10-01

Close Date: 2026-10-01

Grant: Close

Optimising Care: Phase lll Trial in women with metastatic breast cancer to improve quality of life via exercise and diet

Open Date: 2021-01-01

Close Date: 2026-01-01

Grant: Open

Adverse cardiovascular events after cancer: analysis of the NSW 45 and Up cohort

Open Date: 2021-01-01

Close Date: 2032-01-01

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Purpose Cancer significantly impacts First Nations Australians, with higher incidence and lower survival rates. However, understanding of end-of-life (EOL) service use and costs in this population is limited. We aimed to assess EOL healthcare utilisation and costs for First Nations cancer patients in Queensland, Australia. Methods Retrospective data from CancerCostMod, a linked administrative dataset of all cancer diagnoses in Queensland, were used. This dataset includes records from the Queensland Cancer Registry (QCR) from July 1, 2011, to June 30, 2015, linked to Queensland Health Admitted Patient Data Collection (QHAPDC), Emergency Department (ED) Information Systems, Medicare Benefits Schedule (MBS), and Pharmaceutical Benefits Scheme (PBS) data from July 2011 to June 30, 2018. All diagnosed cancer patients who had died during the study period ( N = 467) were included. Health service usage and costs during the last 6 months of life were described and compared across care type, comorbidity status, age group, and residential remoteness using Mann–Whitney and Kruskal–Wallis tests. Results Individuals had at least one hospital episode (100%), ED visit (83%), MBS claim (96%), and PBS claim (96%). The median overall cost per person for hospital episodes was AUD$40,996, with higher costs for those receiving palliative care (AUD$43,521) and chemotherapy (AUD$50,437) compared to those who did not receive these services (palliative: AUD$34,208, chemotherapy: AUD$38,557). Having comorbidities and living in regional and remote areas were associated with higher hospital costs. Conclusion The study findings may guide the re-design and delivery of optimal and culturally appropriate EOL care for First Nations Australians diagnosed with cancer.

Year:

2025

Issue Addressed Lung cancer screening (LCS) is crucial for Indigenous populations due to their higher lung cancer incidence rates and poorer outcomes. Despite efforts to establish LCS programmes, evidence on LCS cost‐effectiveness, participation rates, facilitators and barriers for Indigenous peoples remains limited. This systematic review aims to address this gap by reviewing available evidence. Methods This systematic review conducted searches for relevant articles in PubMed, Scopus, CINAHL, Google Scholar and references/citations of included articles. Results Fifteen out of 19 eligible studies were conducted in the USA, three in New Zealand and one in Canada, with 23 715 Indigenous participants in the 15 quantitative studies. New Zealand studies found that LCS is cost‐effective for Māori, while the participation rate for American Indian/Alaska Natives (4.7%) was lower than for White Americans (21.7%). Facilitators included positive views of LCS, trust in Indigenous‐centred care/providers, trusted invitations, family and community support, transportation or flexible scheduling, culturally competent navigators and detailed health education. Barriers included limited knowledge about LCS/eligibility criteria, fear of the screening process or cancer diagnosis, mistrust or negative experiences in healthcare, cost and time constraints, limited transportation/resources and non‐inclusive eligibility criteria. Conclusions Further research is needed to understand the LCS among Indigenous peoples. Enhancing LCS participation requires leveraging positive experiences and addressing barriers with culturally tailored education and strategic resource allocation. So What? For Australia and similar countries preparing for LCSPs, global evidence highlights the need for adequate resources, integration of Indigenous cultural practices and active involvement of Indigenous communities in programme planning.

Year:

2025

Year:

2025

Year:

2025

The eradication of the commercial tobacco industry is a crucial goal for health and well-being, particularly from a public health and health justice perspective. The term ‘eradication’ is applied in epidemiology to mean the process and outcome of elimination of the—commercial tobacco industry as a human-made—agent of disease and death. In this commentary, we outline why the eradication of the tobacco industry is necessary, urgent and realistic. The potential impact of eradication of the industry is substantial. Without the industry and the commercial tobacco that it produces, it is expected that globally over 22 000 lives will be saved daily (over 8 million annually), and life expectancy will increase. The human right to health underscores the need for tobacco industry accountability for the harms it causes and given the enormous human and financial costs, it is time for action towards eradication of the industry. The tobacco industry’s opposition to tobacco control, particularly strategies focused on market supply and industry reform, has been fierce. Their strategies have involved circumventing, attacking and undermining public health measures to preserve profits. However, with insights learnt from over 70 years of incremental successes in reducing commercial tobacco use, we know that through comprehensive and locally tailored eradication strategies involving legislation, regulation and public health initiatives across multiple levels of governments, we can overcome the resistance from the tobacco industry and their affiliates. Given the cost of commercial tobacco and the ever-growing global consensus on its harms, the time to act is now.

Year:

2025

Objective To quantify costs incurred by the health system for hospital episodes and emergency department (ED) presentations for pancreatic cancer patients within the first three years after diagnosis in Queensland, Australia. Study Settings and Design Using a linked administrative dataset, CancerCostMod, which includes cancer diagnoses from the Queensland Cancer Registry (1st July 2011–30th June 2015) and linked Queensland Health Admitted Patient Data Collection and ED Information Systems records (1st July 2011–30th June 2018), we assessed costs for adults diagnosed with primary pancreatic cancer (International Classification of Diseases, 10th Revision: C25). Costs (in Australian dollars) were assigned using national public costs and private hospital charge datasets for the relevant year. Descriptive analyses were conducted to evaluate hospital and ED utilization and costs. Cost variations across sociodemographic and clinical characteristics were assessed using Kruskal–Wallis or Mann–Whitney U tests. Principal Findings Among 2082 individuals diagnosed with pancreatic cancer, hospital episodes ( n = 26,405) in the first three years after diagnosis cost a total of $100.7 million; median cost per patient was $36,832. For ED presentations ( n = 4228), corresponding figures were $3.6 million (total) and $963 (median per patient). Most of the total hospital (81%) and ED (79%) costs occurred in the first year after diagnosis. Patients who survived ≤ 6 months had the lowest median cost per patient but accounted for 38% of total hospital costs. Median cost per patient varied substantially by socio‐demographic (i.e., Age groups, Indigenous status, socio‐economic disadvantages) and clinical characteristics (i.e., comorbidity, cancer morphology, location of tumor, tumor resection, palliative care). Conclusions Our findings highlight the significant economic burden of pancreatic cancer on the healthcare system, especially within the first year. Targeted strategies are essential to optimize healthcare delivery, ensure equitable access, and improve outcomes.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (21)

Tracey DiSipio

Lecturer

University of Queensland

AUSTRALIA
View details

Jon Emery

Professor of Family Medicine. Director of Research Institute for Cancer Prevention, Screening and Early Detection (RISE)

Nanyang Technological University (NTU)

SINGAPORE
View details

Neal Palafox

Professor

University of Hawaii

UNITED STATES
View details

Fiona Stanaway

-

AUSTRALIA
View details

Penney Upton

Associate professor

University of New South Wales (UNSW) - Canberra

AUSTRALIA
View details

Lisa Whop

Associate Professor, National Centre for Aboriginal and Torres Strait Islander Wellbeing Research

Australian National University

AUSTRALIA
View details

Kalinda Griffiths

Director

Flinders University

AUSTRALIA
View details

Michelle Kennedy (Wiradjuri)

University of Newcastle Australia

AUSTRALIA
View details

Roxanne Bainbridge

Deputy Director, Professor

University of Queensland

AUSTRALIA
View details

Raglan Maddox

Australian National University

AUSTRALIA
View details

Katy Bell

Associate Professor of Clinical Epidemiology

University of Sydney

AUSTRALIA
View details

Emma Webster

Associate Professor Rural Research

-

AUSTRALIA
View details

Rohan Telford

Australian National University

AUSTRALIA
View details

Xiang-Yu Hou

University of the Sunshine Coast

AUSTRALIA
View details

Vivienne Milch

Professorial Fellow

Flinders University

AUSTRALIA
View details

Sue Crengle

Professor

University of Otago

NEW ZEALAND
View details

Wael Al-Delaimy

University of California, San Diego

UNITED STATES
View details

Yaqoot Fatima

Professor

University of the Sunshine Coast

AUSTRALIA
View details

Kwun M. Fong

-

AUSTRALIA
View details

Christina Heris

The Australian National University

AUSTRALIA
View details

Gail Garvey

Professor of Indigenous Health Research

University of Queensland

AUSTRALIA
View details